Gout Drug Colchicine Studied to Treat Pericarditis

November 1, 2011 by Alex.

by AzRedHeadedBrat
by AzRedHeadedBrat
Pericarditis is the inflammation of the pericardium, a fibrous sac that surrounds the heart. It commonly occurs for no known reason, but can also be caused by tuberculosis, cancer, cardiac surgery, viral infections, or an autoimmune disease. Pericarditis is usually painful, and can cause life-threatening fluid accumulation around the heart.

Pericarditis can be treated with anti-inflammatory drugs (such as aspirin, ibuprofen, or a steroid), but recurrences are frequent - occurring in about 50% of patients after their first attack, and one third of patients with acute pericarditis. Some patients have been treated with another drug, colchicine, although there is little data from clinical trials on its effectiveness.

Researchers form Italy's Maria Vittoria Hospital conducted a randomized, double-blind, placebo controlled study to see whether colchicine can help resolve the symptoms and prevent further recurrences of pericarditis. The results were published in the Annals of Internal Medicine.

One-hundred-and-twenty patients who had a first occurrence of pericarditis were randomly assigned to receive either generic colchicine or a placebo pill every day for six months. Both groups also received anti-inflammatory drugs. The researchers found that symptoms of pericarditis improved within one week more often for patients who received colchicine than for those who received a placebo.

Patients who received colchicine also had about half the number of additional episodes of pericarditis during the following eighteen months than those who received the placebo. Gastrointestinal symptoms (such as diarrhea, nausea, or discomfort) were the most frequent side effects, occurring in seven percent of the patients in both groups.

It is also not yet known how long treatment with colchicine should be continued. Patients whose pericarditis was caused by specific infections or cancer, pregnant or breastfeeding women, and patients who had already had more than one incidence of pericarditis were not included in the study, so it's not known whether colchicine would be beneficial or safe for those patients.

Colchicine is not approved for the treatment of pericarditis in the United States or Europe, and this use is considered off-label. But the researchers say the implications of their study are that colchicine is a safe and effective treatment for some patients who have had their first occurrence of pericarditis.

Colchicine has been used as a gout medication since the 1800s, and an estimated three million Americans rely on the gout drug to ease the intense pain of gouty arthritis. The price of colchicine soared in the US in 2010, when URL Pharma was given market exclusivity for their name brand Colcrys, and generic colchicine was ordered off the market.

Generic colchicine is still available in Canada, and American gouty arthritis sufferers can still buy colchicine at a reasonable price through an online pharmacy with a valid prescription.

Filed under: Recurrent Pericarditis, Gout Medications.

Tags: treat gout, gout drug, gouty arthritis, generic colchicine, gout medication, price of colchicine, name brand Colcrys, buy colchicine, www.colchicine.ca.

There are no comments for now. Leave your comments.

Investigational Gout Drugs Do Well in Clinical Trials

November 3, 2011 by Lynn.

from storyofadrug
from storyofadrug
Two major American drug companies are racing to get rival new gout medications to market. Both gout drugs take novel approaches to treating refractory gout - gout that hasn't responded well to current treatment.

Ardea Biosciences was the first to announce successful clinical trials of its experimental gout drug RDEA594, also known as Lesinurad. Lesinurad's mechanism of action is different from that of the commonly prescribed xanthine oxidase inhibitors gout medications (such as allopurinol and febuxostat), which decrease the production of uric acid.

Lesinurad is a URAT1 transporter inhibitor which increases elimination of uric acid through the kidneys. Lesinurad is also active against another important regulator of urate secretion, OAT4. OAT4 is thought to be responsible for the high uric acid levels in gouty arthritis patients whose condition is caused or worsened by diuretics.

The Lesinurad study involved 208 gout patients who had high blood urate levels for at least 6 months, even while taking the gout drug allopurinol. Patients continued on allopurinol and were randomly assigned to receive either a placebo or lesinurad at doses of 200 mg, 400 mg, or 600 mg for four weeks.

All three groups who were given lesinurad showed significantly lower uric acid levels at the end of the month. The percentage of patients who achieved the target for uric acid levels after treatment was 28% in the placebo group, 71% in the 200 mg group, 76% in the 400 mg group, and 87% in the 600 mg group.

More recently, shares of BioCryst Pharmaceuticals rose 12% upon the release of the results of its phase 2b randomized, double-blind, study of the investigational gout drug BCX4208. BCX4208 is a novel enzyme inhibitor that acts upstream of xanthine oxidase in the purine metabolism pathway to reduce serum uric acid (sUA).

Its mechanism of action complements xanthine oxidase inhibitors such as allopurinol and febuxostat in reducing uric acid production, and BCX4208 is intended as an add-on therapy for those gouty arthritis patients who don't respond well to current gout medication.

Like Lesinurad, BCX4208 was studied in gouty arthritis patients who had experienced high blood urate levels for at least 6 months, despite taking the gout drug allopurinol. The 279 study participants were randomly assigned to take BCX4208 at doses of either 5 mg, 10 mg, 20 mg, or 40 mg once daily for 12 weeks. One group of patients was given a placebo. All participants were also given allopurinal 300 mg once-daily.

All but one of the doses showed that BCX4208 was superior to the placebo when taken with allopurinol. The BCX4208 doses evaluated in the study showed response rates ranging from 33% to 49%, compared to 18% for those taking the placebo.

At this point, Lesinurad appears the more promising of the two gout medications, and the most likely to hit the market first. It outperformed BCX4208 in early clinical trials, and is farther ahead in the development and approval process. But individual responses to drugs vary, and gout patients will benefit from having two new approaches to relieving the symptoms of this painful condition.

Filed under: Gout Arthritis.

Tags: prescription allopurinal, gout drug, gouty arthritis, gout medication, allopurinol 300 mg, prescription allopurinal, gout drug allopurinol, buy allopurinol, colchicine for gout, www.colchicine.ca.

There are no comments for now. Leave your comments.

What Does Gout Look Like?

November 8, 2011 by Lynn.

from CNN Health
from CNN Health
The CNN Health website includes a section on gout and gout treatment. The section includes helpful resources such as a Gout Quiz, and an article titled Ten Questions to Ask Your Doctor About Gout.

The section also links to information on the latest in gout medication from Harvard Medical School, including the first new gout medications to be approved in 40 years: prescription Uloric (generic Uloric), and the gout drug Krystexxa (pegloticase), which is effective in breaking down gout tophi.

For those who are still not sure if they are experiencing gout, or those who wonder what gout looks like, the site also includes a series of photos of a gout flare up at the base of the big toe - the most common place for a gouty arthritis attack. To see what gout looks like on CNN Health, >Click Here.<

Filed under: Gout Causes and Symptoms.

Tags: gouty arthritis, gout medication, prescription febuxostat, gout drug, prescription Uloric, generic febuxostat, gout tophi.

There are no comments for now. Leave your comments.

Jim Belushi Helps Launch Gout Awareness Campaign

November 9, 2011 by Estella.

about his battle with gout
about his battle with gout
Jim Belushi has joined with Savient Pharmaceuticals to launch a new educational campaign called "Check Out Your Gout". The campaign is aimed at raising awareness about gouty arthritis, and a severe form of the condition known as refractory chronic gout, or RCG. An actor, singer and performer, Belushi's roles have ranged from comedy to drama, but when it comes to gout, Belushi is completely serious.

"When I first developed gout, I didn't want to do anything about it. I thought I could tough it out; but when the pain became too unbearable for me to perform on stage, I saw a rheumatologist and got my gout under control," said Belushi. "I am taking part in the 'Check Out Your Gout' campaign to let people know that gout is a very painful condition that should be taken seriously, and to tell those who are or may be affected by gout or RCG to check it out and work with a doctor to identify the best management plan."

The campaign encourages people to get serious about gout and to take action to learn more about the condition. The campaign features broadcast and online videos, as well as an educational website, CheckOutYourGout.com.

Gout is a debilitating form of arthritis affecting approximately eight million Americans. Triggered by high levels of uric acid in the blood, gout causes pain and swelling in the joints and can result in deposits of uric acid crystals under the skin, called tophi. RCG occurs when uric acid levels remain high and symptoms persist despite available conventional therapies. RCG symptoms may be particularly debilitating, due to the frequency and severity of episodes, the recurrent painful gout attacks and the disfigurement associated with the condition.

As part of the campaign, Belushi will share his personal experience with gout through national and local media appearances and additional programming planned for next year. "Gout continues to be widely misperceived and overlooked," said Louis Ferrari, Senior Vice President of Savient Pharmaceuticals. "Our hope is that through the 'Check Out Your Gout' campaign Savient, together with Jim, can increase awareness and understanding of gout and RCG."

Savient Pharmaceuticals manufactures and markets the first and only FDA-approved gout medication to treat adults with chronic and severe gouty arthritis that doesn't respond to existing gout drugs. Unlike older oral gout medications such as prescription colchicine, Krystexxa (pegloticase), is given intravenously (into a vein). The pegloticase mechanism of action is different than that of other gout medications, which block the production or increase the excretion of uric acid. Instead, Krystexxa converts uric acid to a nontoxic byproduct that is easily excreted in the urine.

Filed under: Gout and Pseudogout.

Tags: buy colchicine, gouty arthritis, gout medication, gout drugs, gout medications, prescription colchicine, pegloticase mechanism of action.

There are no comments for now. Leave your comments.

About Gout Risks in Youngsters

November 22, 2011 by Derek.

Youngsters from digikuva
Youngsters from digikuva
Gout can be one of the most troubling rheumatic diseases which is supposed to start in men in the age group of 40 to 50 years. However, binge drinking has resulted in a spurt of gouty arthritis among youngsters mostly in their 20s. Many such cases were admitted to emergency wards, and Canada pharmacies are worried similar results may occur in several other places as well.

Diets Rich in Alcohol and Meat Leading To Gout
Gout is caused basically because excess uric acid collects in the blood. People experience extreme arthritis, especially in the joints associated with inflammation and pain. It generally happens in the wrists, big toes, and ankles. Around 80% of gout cases are seen in men, while women normally experience the disease during menopause.

Experts are of the opinion that gout risks among youngsters are increasing because of their sedentary lifestyles and diet rich in meat and alcohol. Gout has been related to proper functioning of the kidneys. Excess alcohol consumption is likely to force the kidneys to malfunction by making it unable to excrete excess amount of uric acid formed in the body.

Also, excess uric acid formed due to alcohol consumption crystallizes and forms deposits in the tendons, joints, and surrounding muscle tissue. Canada Pharmacy Online believes binge drinking is also responsible for increasing the risk of youngsters getting early liver damage and developing hypertension as well.

Gout No Longer Strikes Only the Old
Gout has been gaining ground in the UK and United States as well. There used to be a time when gout was prevalent among people in their 50s, but the number of cases striking people in their 30s and even less has increased drastically over the years. Obesity has been a major factor in the growing obesity rate, and it increased by approximately 17% per year. An increasing number of people buy Colcrys to deal with extreme pain associated with gout.

A study was conducted in the United States where 47,000 men realized that gaining weight in excess of two stone after they turn 21 years old literally doubled the risk of them getting gout. Similarly, overweight people after shedding weight reduce their chances of getting gout by a hefty 40 percent.

Risk of Getting Other Medical Conditions When Gout Strikes Youngsters
Youngsters getting gout also increase the risk of acquiring other medical conditions, and risk factors are not limited to men alone. Women have traditionally increased risk of acquiring gout during menopause. However, hormone replacement therapy (HRT) does reduce the risk. In another study, women having undergone HRT had almost 24% less uric acid. Though these results helped establish positive results, gout does increase the risk of several other ailments if left unattended.

It should send warning of more serious medical conditions like type 2 diabetes and hypertension. Youngsters getting gout due to lifestyle habits like alcohol consumption, fatty food, and very little exercise must warn others as well.

Filed under: Gout Risk.

Tags: gout riks, risk factors for gout, gouty arthritis, buy colcrys, generic colchicine, canadian pharmacies.

There are 1 comment(s). Leave your comments.

Colchicine Lowers the Risk of Atrial Fibrillation (AF)

November 23, 2011 by Estella .

from theheart.org
from theheart.org
Colchicine, an oral anti-gout agent has been used for centuries for the treatment of gout; it was approved in the US in 2007. It is also used to treat familial Mediterranean fever (FMF).

In the latest study from COPPS (Colchicine for the Prevention of the Postpericardiotomy Syndrome), Colchicine therapy could become a safe and inexpensive way to prevent post-surgery of atrial fibrillation. The result showed patients on Colchicine had a significantly reduced incidence of postoperative AF between days 3 and 30, with a relative risk reduction of 45.5%, compared with those taking placebo (p=0.021). Colchicine use was also associated with a shorter in-hospital stay.

However, Dr Nancy Nussmeier (SUNY Upstate Medical University, Syracuse, NY), anesthesiologist, told heartwires: I don't recommend the routine use of colchicine for the prevention of postoperative AF on the basis of a single trial. We need further multicenter trials to confirm this. Read the full article, >Click here<.

Filed under: Atrial Fibrillation.

Tags: colchicine, colchicine for gout, gout medication, gout drug, anti-inflammatory, risks of atrial fibrillation, post-op, postoperative atrial fibrillation.

There are no comments for now. Leave your comments.

Effective Colchicine Therapy for Recurrent Pericarditis

November 25, 2011 by Derek.

Heart Smart
Heart Smart
Inflammation of pericardium, the fibrous sac enclosing the heart, is a medical defect known as pericarditis. Patients often experience chest pain, swelling in the ankles and feet. Shortness of breath while lying down and anxiety are other symptoms. Our Canada pharmacy found more people purchase colchicine to prevent recurrent pericarditis.

Colchicine is an oral drug used to treat gout and familial Mediterranean fever (FMF) and is useful in suppressing inflammation. A recent trial now finds the prescription drug more effective than placebo in preventing recurrent and persistent symptoms of pericarditis in conjunction with conventional therapy. A double-blind multicenter randomized trial, the first of its kind, demonstrates effectiveness of the medication.

Trial Conducted To Verify Non-Randomized Observational Findings
Pericarditis has a common complication in that it is recurrent in about 20% to 50% cases of people who have experienced the medical condition earlier. Recurrent pericarditis is a disabling disease seriously affecting quality of life. Frequency at which it occurs makes re-hospitalization necessary. Efficient management is needed to keep treatment costs down. Open-label randomized studies conducted at two centers and non-randomized observational findings already revealed effectiveness of colchicine in preventing recurrent pericarditis. Experts were therefore of the opinion further tests were needed to verify results. Our Canada pharmacy followed up on the multi-center trial.

Experts from the European Society of Cardiology recommended colchicine in its 2004 guidelines for pericardial diseases, which initiated the CORP trial in four centers in Italy. The trial was conducted on 120 consecutive patients who experienced pericarditis for the first time. A primary endpoint was set up to check recurrence of pericarditis at the end of 18 months.

Several secondary endpoints were also set up. Recordings included checks to measure persistence of symptoms at the end of 72 hours, number of times the condition occurred, rate of remission at the end of the week, first recurrence, rate of constrictive pericarditis, cardiac tamponade, and hospitalization due to pericarditis.

Volunteers were given an initial dose of 1 to 2 mg on the day of starting the trial followed by 0.5 to 1 mg daily for the next six months. The lower initial and maintenance dozes were given to people below the rate of 70 kg and those who demonstrated intolerance to higher doses.

Positive Results Encourage Usage of Colchicine
Trial results clearly indicated colchicine was more effective than placebo. For example, the 18-month recurrence rate reduced by 55% in the case of colchicine compared to just 24% in the case of placebo. The mean number of recurrent episodes also reduced in favor of colchicine. At the end of 72 hours, persistent symptoms were 23% compared to 53.3% in placebo cases. Also, people found faster relief in 82% cases compared to 48% in people using placebo.

Colchicine is known to be a safe drug available at low cost at a Canada pharmacy. Further trials may be needed including people from other geographical locations and in more generalized settings; however, the prescription drug does provide rapid relief from symptoms of pericarditis. Its effectiveness over the 18-month period makes it an ideal medication to be added to empiric anti-inflammatory therapy for prevention of recurrent pericarditis.

Filed under: Colchicine Use, Recurrent Pericarditis.

Tags: colchicine, therapy, recurrent pericarditis, CORP, gout medication, buy colchicine.

There are 1 comment(s). Leave your comments.

Arcalyst for Gout under Review by FDA

November 29, 2011 by Estella .

from Regeneron Pharm
from Regeneron Pharm
Regeneron Pharmaceuticals Inc. announced that FDA will review its drug Arcalyst as a treatment for gout. FDA plans to complete this review by July 30, 2012.

Arcalyst (rilonacept) is currently approved to treat Cryopyrin-Associated Periodic Syndromes (CAPS), a rare genetic anti-inflammatory disease. Regeneron reported $5.5 million in sales of the drug during the third quarter.

Regeneron is a fully integrated biopharmaceutical company markets two main products: Arcalyst (rilonacept) injection for subcutaneous use and Zaltrap (aflibercep) injection. Additional information about Regeneron and recent news releases are available at www.regeneron.com.

Filed under: Gout Treatment and Prevention, Gout Medications.

Tags: arcalyst, rilonacep, fda review, gout treatment, gouty arthritis, new gout drug.

There are no comments for now. Leave your comments.
Most Recent Posts